In this Phase III trial, 243 high risk patients were randomised to receive adjuvant RT (n=116) alone vs combined concurrent chemoradiotherapy (n=127). High risk patients were defined as Stage 1A2, 1B or 2A cervical malignancy with any of the following: positive pelvic lymph node, positive parametrium or positive surgical margin. Patients were randomised to receive pelvic radiotherapy (RT) or pelvic RT with 4 cycles of chemotherapy (CRT). Patients receiving RT were prescribed a dose 49.3Gy in 29 fractions, and chemotherapy consisted of 4 cycles of cisplatin (70 mg/m2, day 1) and infusional 5FU (1000mg/m2/day, days 1-4), with the first two cycles given concurrent with RT. The primary end point was overall survival, and secondary end points included progression-free survival, recurrence rates and toxicity. Data was analysed after a median follow-up of 42 months.r. ...
Overall survival (OAS) and disease-free survival (DFS) for TNBC patients who received 100% guideline-adherent adjuvant treatment, as stratified by age (|50 n
Disease-free survival curve (A) and overall survival curve (B) according to CD44s protein expression. CD44s expression correlates with a negative prognosis (A),
Bone Metastasis-Free Survival. The median follow-up was 67.2 months in the denosumab group and 67.3 months in the placebo group. Median bone metastasis-free survival was not reached in either group (hazard ratio [HR] = 0.97, 95% confidence interval [CI] = 0.82-1.14, P = .70). Bone metastasis-free survival events occurred in 13% of the denosumab group vs 14% of the placebo group, including bone events in 7% vs 8%. Median disease-free survival was not reached in either group (HR = 1.04, P = .57). Disease-free survival events occurred in 20% vs 19% of patients.. Adverse Events. The most common grade ≥ 3 adverse events were neutropenia (15% vs 15%), febrile neutropenia (5% vs 6%), and leukopenia (3% vs 3%). Positively adjudicated osteonecrosis of the jaw occurred in 5% vs , 1% of patients. Atypical femur fracture occurred in nine patients (, 1%) vs no patients. Hypocalcemia of any grade occurred in 7% vs 4%.. The investigators concluded, "Despite preclinical evidence suggesting RANKL inhibition ...
TY - JOUR. T1 - Long-term efficiency and toxicity of adjuvant dose-dense sequential adriamycin-paclitaxel-cyclophosphamide chemotherapy in high-risk breast cancer. AU - Kelemen, Gyöngyi. AU - Uhercsák, Gabriella. AU - Ormándi, Katalin. AU - Eller, József. AU - Thurzó, László. AU - Kahán, Zsuzsanna. PY - 2010/6/1. Y1 - 2010/6/1. N2 - Objectives: To perform a protocol-specified analysis of the dose-dense adriamycin-paclitaxel-cyclophosphamide (ddATC) study. Methods: Survival and late toxicity were analyzed in 55 patients enrolled to receive 4 × adriamycin 60 mg/m2, 4 × paclitaxel 200 mg/m2, 4 × cyclophosphamide 800 mg/m2, every 2 weeks, with cardioxane and filgrastim support. Kaplan-Meier curves were used to analyze relapse-free survival (RFS), distant disease-free survival (DDFS), and overall survival (OS). Survival analyses were performed according to the presence of casting-type calcifications on the mammogram. Results: After a median follow-up time of 78.5 (64.3-100.0) months, 29 ...
response rate, stable disease rate evaluated by RECIST criteria, median overall and disease-free survival time, 1-year overall and disease-free survival rate, toxicity and time to disease ...
The major efficacy outcome was progression-free survival assessed by independent review committee. The median progression-free survival was not reached in either group. After median follow-up of 28 months, progression-free survival events occurred in 13% of the venetoclax group vs 37% of the control group, demonstrating a significant improvement in the venetoclax group (hazard ratio = 0.33, P , .0001). Overall response rates were 85% in the venetoclax group vs 71% in the control group (P = .0007). The venetoclax group also had improvements in the rates of minimal residual disease negativity (less than 1 CLL cell/104 leukocytes) in bone marrow (57% vs 17%) and peripheral blood (76% vs 35%). Overall survival data were not mature.. How It Works. Venetoclax is a selective small-molecule inhibitor of the antiapoptotic protein BCL2. BCL2 has been found to be overexpressed in CLL and acute myeloid leukemia cells, where it mediates tumor cell survival and has been associated with resistance to ...
Initially, patients in the trials were given a series of up to six inoculations of NeuVax dosed once a month. As the trials progressed, the physicians noticed that E75-specific immunity waned after this initial monthly Primary Vaccine Series (PVS) and translated to late recurrences of cancer in some patients. This declining immunity was identified by monitoring the level of CD8 T-cells in each of the patients. Through this evaluation, it became clear that immunological boosters would keep the level of circulating E75-specific CD8+ T cells elevated during the conduct of the trial. As a result of this finding, a voluntary booster program was added to the trials to maintain long-term immunity following the initial monthly PVS ...
SAN ANTONIO, Dec. 07, 2017 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib in combination with standard of care agents demonstrated prolonged progression-free survival (PFS) in a subgroup of patients participating in two ongoing Phase 1b studies. Results from a subgroup analysis from these tucatinib combination studies showed 22 percent…
Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Improved Progression-Free Survival with Iressa as Adjuvant Therapy for EGFR Mutation Positive Patients.
All analyses were performed based on the intention-to-treat principle, irrespective of process compliance, but five individuals in the intermediate-dosage group and four in the high-dosage group were excluded as ineligible . Cox regression analysis was used to investigate the effects of treatment group and covariates on event-free survival and general survival. These analyses were performed […]. ...
KEYTRUDA (pembrolizumab) in Combination w/Chemo Significantly Improved Progression-Free Survival Compared to Chemo Alone for Extensive Stage SCLC
Antigenics has announced top-line results from its Phase III study of Oncophage (vitespen) in kidney cancer patients who are at high risk of recurrence after surgery. The analysis was triggered based on the number of events (defined as recurrence of disease or death of a patient prior to recurrence) reported by study investigators. However, an independent review by the trials clinical events committee (CEC) revealed that a substantially smaller number of events had actually occurred. The analysis showed a trend in favor of Oncophage for recurrence-free survival (the studys primary endpoint), and a trend against Oncophage for overall survival (secondary endpoint); both findings were not statistically significant. The results of the CEC review revealed that the required number of events to conduct analysis of the recurrence-free survival endpoint was not met. The analysis of the overall survival endpoint is considered an interim assessment. At this time, it is unclear as to why opposing trends ...
The size, stage, rate of growth, and other characteristics of the tumor determine the kinds of treatment. Treatment may include surgery, drugs (hormonal therapy and chemotherapy), radiation and/or immunotherapy. Surgical removal of the tumor provides the single largest benefit, with surgery alone being capable of producing a cure in many cases. To somewhat increase the likelihood of long-term disease-free survival, several chemotherapy regimens are commonly given in addition to surgery. Most forms of chemotherapy kill cells that are dividing rapidly anywhere in the body, and as a result cause temporary hair loss and digestive disturbances. Radiation is indicated especially after breast conserving surgery and substantially improves local relapse rates and in many circumstances also overall survival. Some breast cancers are sensitive to hormones such as estrogen and/or progesterone, which makes it possible to treat them by blocking the effects of these hormones ...
An independent review of the Dalmatian Backcross Project conducted by Irvin B. Kruckenkamp MD, Dalmatian Club of America Foundation
566 pts were contemporaneously randomised: 189 SOC+DocP (the last of 592 SOC+DocP pts) & 377 SOC+AAP (the first of 960 SOC+AAP pts). Groups were well balanced with 342 (60%) M1; 429 (76%) Gleason 8-10; 449 (79%) WHO PS 0; median age 66yr & PSA 56ng/ml. At median follow up 4 yr, there were 149 deaths (45 SOC+Doc, 111 SOC+AAP): survival HR 1.16 (0.82-1.65); failure free survival HR = 0.51 (0.39-0.67); progression free survival HR 0.65 (0.48-0.88); metastases free survival HR 0.77 (0.57-1.03); & SRE HR 0.83 (0.55-1.25). There was no heterogeneity by baseline M0/M1. Grade 3, 4, 5 toxicity was 36%, 13%, 1% SOC+DocP, & 40%, 7%, 1% SOC+AAP. Subsequent treatments varied by arm, with much crossing after progression.. ...
New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in Resected High-Risk Melano
Reviews of the best places to buy PhenQ. Make sure youre getting quality product. Does GNC, Amazon or Walmart sell it? Are there coupons and price savings?
Disease-free survival and infection assessed monthly for 6 months, every 3 months for 2 years, every 6 months for 1 year, and then yearly for 5 years post ...
Melhores hotéis: Londres no TripAdvisor: veja 94.124 dicas e avaliações, 33.456 fotos e ótimas ofertas e preços para 30 hotéis: Londres, Inglaterra, Reino Unido.
Melhores hotéis: Madri no TripAdvisor: veja 45.457 dicas e avaliações, 24.812 fotos e ótimas ofertas e preços para 30 hotéis: Madri, Espanha.
ਓਸਮੀਅਮ (ਯੂਨਾਨੀ ਓਸਮੇ (ὀσμή) ਭਾਵ "ਗੰਧ" ਤੋਂ) ਇੱਕ ਰਸਾਇਣਕ ਤੱਤ ਹੈ ਜਿਹਦਾ ਨਿਸ਼ਾਨ Os ਅਤੇ ਐਟਮੀ ਸੰਖਿਆ 76 ਹੈ। ਇਹ ਪਲੈਟੀਨਮ ਪਰਵਾਰ ਦੀ ਇੱਕ ਸਖ਼ਤ, ਕੁੜਕਵੀਂ, ਨੀਲੀ-ਚਿੱਟੀ ਪਰਿਵਰਤਨ ਧਾਤ ਹੈ ਅਤੇ ਸਭ ਤੋਂ ਘਣਾ ਕੁਦਰਤੀ ਤੱਤ ਹੈ। ਇਹ ਕੁਦਰਤੀ ਤੌਰ ਉੱਤੇ ਜ਼ਿਆਦਾਤਰ ਧਾਤ-ਮਿਸ਼ਰਨ ਵਜੋਂ ਪਾਇਆ ਜਾਂ ਦਾ ਹੈ, ਖ਼ਾਸ ਕਰ ਕੇ ਪਲੈਟੀਨਮ ਦੀਆਂ ਕੱਚੀਆਂ ਧਾਤਾਂ ਵਿੱਚ। ...
ಜನವರಿ 2005ರಲ್ಲಿ, Lasco.A ಎಂದು ಹೆಸರಾದ ಸಂಚಾರಿ ದೂರವಾಣಿ ಜಾಹಿರಾತುರೂಪಿ ವರ್ಮ್‌ವೊಂದು Symbian OS (ಸೀರೀಸ್‌ 60 ವೇದಿಕೆ) ಬಳಸುವ ಸಂಚಾರಿ ದೂರವಾಣಿಗಳನ್ನು ಗುರಿಯಾಗಿಟ್ಟುಕೊಂಡು Bluetooth-ಸಶಕ್ತ ಸಾಧನಗಳನ್ನು ಬಳಸಿಕೊಂಡು ವೃದ್ಧಿಯಾಗತೊಡಗಿದುದಲ್ಲದೇ ಮತ್ತು ಇತರ ಸಾಧನಗಳಿಗೆ ಹರಡತೊಡಗಿತು. ಇದೊಂದು ಸ್ವಯಂ-ಸ್ಥಾಪಕ ವರ್ಮ್‌ ಆಗಿದ್ದು ಇನ್ನೊಂದು ಸಂಚಾರಿ ದೂರವಾಣಿ ಬಳಕೆದಾರರು ಇನ್ನೊಂದು ಸಾಧನದಿಂದ (ವೆಲಾಸ್ಕೊ.ಸಿಸ್‌) ಕಡತ ವರ್ಗಾವಣೆಗೆ ಒಪ್ಪಿಗೆ ಸೂಚಿಸಿದೊಡನೆ ...
In this prospectively identified cohort of parous women with IBC, we found that a positive breastfeeding history decreases the risks of LRR and DM and, accordingly, that women with a positive breastfeeding history have significantly improved DFS, even after well-defined predictive and prognostic variables are accounted for.. To date, there are no defined molecular alterations or signatures with adequate sensitivity and specificity to discriminate IBC from non-IBC. A potential explanation is that IBC is not a unique molecular entity but rather a manifestation of non-IBC that arises in a microenvironment primed to promote the IBC phenotype [8]. Thus, studies aimed at understanding the IBC microenvironment, and even properties of the normal breast parenchyma that exist before a tumor-initiating event, may illuminate the pathobiology of IBC.. The mammary epithelium undergoes massive expansion during pregnancy, and studies in mice have demonstrated that the abundance of mammary stem cells also ...
In the first study, the primary endpoint was response rate, and secondary endpoints were time to disease progression, progression-free survival, overall survival and safety. This was met with patients receiving amrubicin demonstrating an overall response rate of 34 percent, compared to 3.8 percent of patients receiving topotecan and the median progression-free survival time for amrubicin patients is 138 days compared to 106 days for topotecan. In the second multi-center international study, patients with SCLC who were refractory to first-line platinum based chemotherapy were treated with IV amrubicin . The primary endpoint was response rate, and secondary endpoints were time to disease progression, progression-free survival, overall survival and safety. The overall response rate for the study was 17.4 percent with one complete response, which compares favorably with those seen historically with topotecan. Additionally, median progression-free survival is 97 days. Amrubicin is generally well ...
The treatment of Ph-positive acute lymphoblastic leukemia (Ph+ ALL) has entranced tyrosine kinase inhibitors (TKIs) era. Currently both imatinib and dasatinib are registered as the front-line treatment for Ph+ ALL, and the other 2nd-generation TKIs are suggested as an alternative for those who failed the first-line treatment. However, it remains unclear who could benefit from the 2nd-generation TKIs as the first-line treatment for Ph+ ALL. In this study we compared the efficacy and safety of the 1st and 2nd-generation TKIs in the front-line treatment of Ph+ ALL and found a trend toward better disease-free survival (DFS) in the 2nd-generation TKIs group, though no significant difference in early response and long-term survival between the two groups ...
Several imaging studies have demonstrated strong correlations between infarct size and adverse outcomes in patients with acute MI.29-32 Wu et al31 reported significant associations of the extent of MI and microvascular obstruction by CMR to subsequent cardiac events. Hombach et al32 described similar findings and also reported an association with adverse LV remodeling. Patients without a history of MI who present with cardiac symptoms represent a challenging population that can benefit from accurate risk assessment. Although we observed strong prognostic associations of the presence of LGE with MACE and cardiac mortality, the observed "threshold effect," in which patients in the lowest LGE% tertile (,2% of the LV mass involved) experienced a ,7-fold hazard increase to MACE, has important clinical implications. This low threshold effect of LGE% on outcome is the anatomic representation of similar prior observations involving biomarkers of MI and risk of future cardiac events. Large-scale clinical ...
The team found that the transplantation rate was comparable between the Milan and down-staging groups, at 68% versus 67%, respectively. The researchers noted that the 1 and 3 years disease-free survival rates were comparable.. The 1 and 3 years disease-free survival rates were 80% and 71% in the Milan group versus 78% and 71% in the down-staging group. The actuarial intention-to-treat survival was 56% in the down-staging and 63% in the Milan group. Dr Ravaioli s team concluded, The proposed down-staging criteria provide a comparable outcome to the conventional criteria. ...
The researchers examined the relationships between the inflammation biomarkers and both overall survival and disease-free survival. Overall survival was defined as the amount of time from the follow-up appointment until the patient died (from any cause) or the study period ended. Disease-free survival was defined as the amount of time from the follow-up appointment until the patients breast cancer returned, another, new cancer was diagnosed, the patient died, or the study period ended. The researchers found that elevated levels of both SAA and CRP were associated (statistically significant) with reduced overall survival. Women with high levels of SAA were three times as likely to die sooner, and women with high levels of CRP were two times as likely to die sooner. They found similar, but weaker, associations with disease-free survival, in that women with high levels of SAA were two times as likely to die of have their cancer return, and women with high levels of CRP were more than 1.5 times as ...
Purpose: The G1-S checkpoint of the cell cycle is frequently dysregulated in breast cancer. Palbociclib (PD0332991) is an oral inhibitor of CDK4/6. Based upon preclinical/phase I activity, we performed a phase II, single-arm trial of palbociclib in advanced breast cancer.. Experimental Design: Eligible patients had histologically confirmed, metastatic breast cancer positive for retinoblastoma (Rb) protein and measureable disease. Palbociclib was given at 125 mg orally on days 1 to 21 of a 28-day cycle. Primary objectives were tumor response and tolerability. Secondary objectives included progression-free survival (PFS) and assessment of Rb expression/localization, KI-67, p16 loss, and CCND1 amplification.. Results: Thirty-seven patients were enrolled; 84% hormone-receptor (HR)+/Her2−, 5% HR+/Her2+, and 11% HR−/Her2−, with a median of 2 prior cytotoxic regimens. Two patients had partial response (PR) and 5 had stable disease ≥ 6 months for a clinical benefit rate (CBR = PR + 6moSD) of 19% ...
Two agents blocking HER2 led to an additional six months of progression-free survival. Side effects were minimal with the addition of pertuzumab. Results published in the New England Journal of Medicine. SAN ANTONIO - Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients…
There was no statistical difference in the 8 year local recurrence free survival in patients with VNPI scores of 3 or 4, regardless of whether or not radiation therapy was used (100% vs. 97%; P = not significant). Patients with VNPI scores of 5, 6, or 7 received a statistically significant 17% local recurrence free survival benefit when treated with radiation therapy (85% vs. 68%; P = 0.017). Patients with scores of 8 or 9, although showing the greatest relative benefit from radiation therapy, experienced local recurrence rates in excess of 60% at 8 years. Conclusions: ...
Provide an updated and comprehensive evaluation of the prognostic value of the albumin-fibrinogen ratio (AFR) and the fibrinogen-prealbumin ratio (FPR) for patients with cancer. Four databases (PubMed, Web of Science, Cochrane Library, and WanFang) were searched. The primary endpoints were overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS). Pooled data were synthesized using StataMP 14 and expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). This update examined 19 studies (7282 cases) that assessed the correlation of AFR with cancer prognosis. Pooled univariate and multivariate analyses indicated significant correlations of low AFR with poor OS (HR 2.18, 95%CI 1.87-2.55 and HR 1.75, 95%CI 1.54-2.00, respectively), poor DFS (HR 1.89, 95%CI 1.54-2.32 and HR 1.51, 95%CI 1.29-1.76, respectively), and poor PFS (HR 1.68, 95%CI 1.42-1.99 and HR 1.48, 95%CI 1.16-1.88, respectively). Pooled univariate and multivariate analyses of 6 studies (2232 cases)
After matching at a 1:2 ratio, 150 patients were treated with CCRT and 75 with CCRT plus C were selected. The 3-year PFS rates (83.7% vs 72.0%, P = 0.036) and 3-year LRFS rates (98.6% vs 90.2%, P = 0.034) were higher for patients in the CCRT plus C arm than with CCRT alone. Furthermore, a marginal trend of increasing risk of 3-year DMFS rates (83.9% vs 78.4%, P = 0.301) and 3-year OS rates (91.2% vs 85.8%, P = 0.123) was found. The results indicated that CCRT plus C treatment was a significant and independent protective predictor for 3-year PFS (P = 0.015) and LRFS rates(P = 0.047). When focusing on stage T4 and/or N3 in the subgroup, the CCRT plus C arm achieved significantly prolonged 3-year PFS (79.9% vs 62.6%, P = 0.022) and a marginally increased OS (88.0% vs 77.9%, P = 0.086) compared with that of CCRT alone. Additionally, the 3-year LRFS (97.0% vs 90.9%, P = 0.246) and DMFS (79.9% vs 67.8%, P = 0.161) were enhanced in patients with CCRT plus C compared to CCRT alone. When concentrating on ...
TORONTO, June 2, 2014- Ibrutinib RESONATE(TM) Data Show Significant Improvements in Progression-Free Survival and Overall Survival in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
/CNW/ - New study results show that superior progression-free survival occurred in previously untreated patients with advanced melanoma when treated with a new...
Prolonging Progression-Free Survival With Obinutuzumab-Based Induction in Patients With Previously Untreated Follicular Lymphoma - ASH Annual Meeting, On Location - ASH Clinical News
Background: In HCC, hypoxia and MET can promote tumor progression and induce resistance to radiation, chemo or targeted therapies. The aim of this study was to correlate MET and hypoxia marker carbonic anhydrase 9 (CA9) expression levels by immunohistochemistry with clinicopathological characteristics and disease-free survival (DFS) in patients with HCC.. Material and methods: One-hundred HCC resection specimens were evaluated by immunohistochemistry for MET (clone sp44, Ventana) and CA9 (rabbit polyclonal) expression. For automated evaluation, we elaborated our own macro using ImageJ software, and compared it with H- and MetMab validated scores. METhigh and CA9high expression were defined as moderate to strong staining. Staining results were correlated with clinicopathological characteristics. Univariate analyses were performed using Fishers exact or chi square tests, and multivariate analyses using Cox regression model. Median DFS (mDFS) were calculated by Kaplan-Meier method. MET ...
Novartis says late-stage clinical data show that its cancer drug Afinitor extended progression-free survival in patients with advanced nonfunctional neuroendocrine tumours (NET) of gastrointestinal or lung origin. - News - PharmaTimes
An important problem in oncology is comparing chemotherapy (chemo) agents in terms of their effects on survival or progression-free survival time. When the goal is to evaluate individual agents, a difficulty commonly encountered with observational data is that many patients receive a chemo combination including two or more agents. Because agents given in combination may interact, quantifying the contribution of each individual agent to the combinations overall effect is problematic. Still, if on average combinations including a particular agent confer longer survival, then that agent may be considered superior to agents whose combinations confer shorter survival. Motivated by this idea, we propose a definition of individual agent effects based on observational survival data from patients treated with many different chemo combinations. We define an individual agent effect as the average of the effects of the chemo combinations that include the agent. Similarly, we define the effect of each pair ...
In the control group patients experienced inhibition of myelopoiesis, toxic damage to the kidneys, myocardium, and liver, and signs of immunodeficiency. Under the influence of EIFT there was marked decrease in the degree of endotoxic syndrome. In the control group the most common grade 3-4 toxicity was neutropenia (32.6%) and the metabolic disorders (27.3%). After the EIFT grade 3-4 toxicities are no longer met, with the exception of alopecia. Median progression-free survival (PFS) in the group with EIFT was 7.2 months (95% CI 6.5-7.9), in the group with EIFT and plasmapheresis - 7.7 months (95% CI 7.2-8.2), and in the control group - 5.7 months, (95% CI 4.8-6.6), (p = 0.0031). Median overall survival (OS) in the group with EIFT was 13.5 months (95% CI 11.3-15.7), in the group with EIFT and plasmapheresis - 14.2 months (95% CI 12.1-16.3), and in the control group - 12.4 months (95% CI 10.8-13.9; p = 0.0027). Observable risk ratio (hazard ratio, HR) of progression in the group with EIFT (HR ...
The size, stage, rate of growth, and other characteristics of the tumor determine the kinds of treatment. Treatment may include surgery, drugs (hormonal therapy and chemotherapy), radiation and/or immunotherapy. Surgical removal of the tumor provides the single largest benefit, with surgery alone being capable of producing a cure in many cases. To somewhat increase the likelihood of long-term disease-free survival, several chemotherapy regimens are commonly given in addition to surgery. Most forms of chemotherapy kill cells that are dividing rapidly anywhere in the body, and as a result cause temporary hair loss and digestive disturbances. Radiation may be added to kill any cancer cells in the breast that were missed by the surgery, which usually extends survival somewhat, although radiation exposure to the heart may cause heart failure in the future. Some breast cancers are sensitive to hormones such as estrogen and/or progesterone, which makes it possible to treat them by blocking the effects ...
Purpose Adjuvant therapy for intermediate-risk and high-risk localized prostate cancer decreases the number of deaths from this disease. Surrogates for overall survival (OS) could expedite the evaluation of new adjuvant therapies. Methods By June 2013, 102 completed or ongoing randomized trials were …
Researchers reviewed the results of 18 studies that included 1638 patients with HPV-tested vulvar cancers, of which 541 were HPV-positive.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (NASDAQ ONXX) today announced the full results from their first collaborative group-sponsored ra
Results. Significant skin and lung function improvement of the mRSS was achieved in 78.3% of patients at Month 6. The overall response rate was 91%, as some patients improved even after Month 6. Three patients died between mobilization and conditioning treatment, 2 due to severe disease progression and 1 whose death was considered treatment-related (i.e., GCSF or CYC toxicity). Depending on definitions, transplant-related mortality was 4% and treatment-related mortality 11%. Seven patients experienced a relapse during the 4.4 years of followup. The progression-free survival was 74%. Four patients died during followup and the most frequent causes of death were pulmonary and cardiac complications of SSc. ...
Breast, Breast Cancer, Cancer, Cyclooxygenase, Cyclooxygenase-2, Developed Countries, Disease, Disease-free Survival, Estrogen, Human, Matrix Metalloproteinase-2, Membrane, Metastasis, Mt1-mmp, Multivariate Analysis, Neoplasm, Patients, Progesterone, Progesterone Receptor, Prognosis
Get help choosing the best business software for your company. Over 4000+ products reviewed and download premium software research.
No significant difference in progression-free survival between patients who received maintenance therapy after bendamustine-rituximab induction.
Read independent reviews on Harvest Plate, White 96-Well Microplate with 1.2 µm poresize GF/C filter from PerkinElmer, Inc. on SelectScience